0.5mg Semaglutide: What This Dose Is For and What to Expect

Where 0.5mg sits in the licensed titration schedule

Wegovy's dose ladder exists for a practical reason: semaglutide's most common side effects are gastrointestinal, and starting at a lower dose gives your gut time to adapt before the medicine reaches the concentrations that drive meaningful appetite reduction. The 0.25mg pen is the first four weeks; 0.5mg is the next four. If you want to understand how the journey begins before this point, our guide to the 2.5mg semaglutide starting dose explains what that earlier phase involves. The NHS medicines page for semaglutide sets out this progression clearly, and the prescriber overseeing your treatment decides whether to advance, hold or adjust at each stage.

At 0.5mg you are still below the doses used in the STEP 1 trial's therapeutic phase. That matters for expectation-setting. Some people notice early appetite changes; others feel little different from the starting pen. Neither response predicts how the full course will go. The prescriber's job is to read that picture with you.

One practical note: if a dose increase falls near a bank holiday or a period when you're away, plan ahead. Our prescribers can work around your schedule when you flag it at consultation, there's no rigid clock that punishes a few days' flexibility, but your prescriber should know about any planned gap.

What 0.5mg semaglutide typically feels like, side effects at this stage

Nausea is the side effect patients mention most at this point. For many people it peaked at 0.25mg and is already settling; for others 0.5mg brings a brief second wave as the dose steps up. Loose stools, constipation, burping and a general sense of reduced hunger are also commonly reported. These effects are usually mild to moderate and tend to ease within a week or two of the new dose.

The STEP 1 trial, which enrolled 1,961 adults over 68 weeks, showed the gastrointestinal side-effect profile was most pronounced during titration and diminished at maintenance. That pattern is well-established, it is one reason the schedule exists. Fatigue and headache are also noted in the early weeks, though they are less common than GI symptoms.

More serious symptoms require prompt attention: severe abdominal pain that radiates to the back could indicate pancreatitis, get urgent medical help if that happens. The MHRA highlighted acute pancreatitis as a known risk in its January 2026 Drug Safety Update for GLP-1 medicines. Suspected side effects can be reported at the MHRA's Yellow Card scheme. For day-to-day questions about tolerating a dose, our aftercare team is available seven days a week.

Results at 0.5mg, and what the full trial data says about where the weight loss happens

Expecting significant weight loss at 0.5mg sets up a false benchmark. The clinical evidence is clear on this: the STEP 1 trial's headline figure (roughly 15% average body-weight reduction over 68 weeks) was achieved at 2.4mg maintenance, not during the early titration weeks. Participants who progressed through the schedule saw cumulative benefit build over months, not the first few injections.

This does not mean 0.5mg is doing nothing. The early doses establish the physiological changes (appetite signalling, gastric emptying, insulin response) that the higher doses then amplify. Think of the titration phase as laying groundwork. If you'd like a fuller picture of how results unfold across the schedule, the semaglutide results at this dose page goes deeper on the evidence by phase.

For context on how semaglutide compares across its full dose range, the Wegovy doses overview maps each step against the trial evidence. And if you're weighing up where in the schedule a private prescription might start, the semaglutide dosing guide covers how prescribers approach that decision. Eligibility, route of access and what a consultation involves are all covered on the Wegovy treatment page.

Moving beyond 0.5mg, when and how titration continues

Four weeks at 0.5mg is the standard interval before the prescriber considers advancing to 1.0mg, but this is not automatic. If side effects are still significant, the prescriber may recommend staying at 0.5mg for another cycle. That is not a failure, it is the schedule working as designed. Rushing titration because of impatience is the most common reason people end up with unnecessary side effects at higher doses.

The next dose up, 1.0mg, is where many patients begin to notice more consistent appetite suppression. From there the ladder continues to 1.7mg and then 2.4mg. The MHRA approved a 7.2mg maintenance option in early 2026, available via a dedicated single-dose pen, for eligible adults with a BMI of 30 or above, though specific dose availability is always confirmed at consultation rather than assumed. Details on that higher dose sit in the 0.5mg Wegovy pen guide and the broader weight management treatment overview.

Semaglutide is a prescription-only medicine. Every step of the dose schedule is directed by your prescriber, not self-managed. If you're considering starting or are already on treatment and want clinical oversight that keeps pace with where you are in the titration, the right starting point is a consultation rather than guesswork. Speak to our prescribers to discuss your situation.